• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

New Search Back To Search Results
Part B: Supplementary Information Sheet (SIS)
FR Recognition List Number 051 Date of Entry 01/14/2019 
FR Recognition Number 7-286
Standard
CLSI M11 9th Edition Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Eighth Edition.
Scope/Abstract
Susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy if its susceptibility cannot reliably be predicted from existing antibiograms. Antimicrobial resistance patterns for many anaerobic bacteria have changed significantly over the last several years, resulting in a lack of predictability for many species. Susceptibility testing of anaerobes is recommended for surveillance purposes and for specific clinical situations.

Two end-point-determining susceptibility testing methods for anaerobic bacteria are described in Clinical and Laboratory Standards Institute document M11-A8 - Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eighth Edition. The agar dilution method (Wadsworth) remains the reference standard, and is well suited for surveillance testing and research. It is also the standard to which other methods are compared. Broth microdilution is well suited for the clinical laboratory, but is currently limited to testing of Bacteroides fragilis group organisms and selected antimicrobial agents. QC criteria for each procedure are also described.

The tables in CLSI document M100,1 when used in conjunction with this standard, represent the most current information for drug selection, interpretation, QC, and antibiogram reports using the procedures standardized in M11. Users should replace tables published in earlier standards with these new tables. (Changes in the tables since the previous edition appear in boldface type). When new problems are recognized, or improvements in these criteria are made, changes will be incorporated into future editions of this standard and also distributed as informational supplements.
Extent of Recognition
Complete standard
Rationale for Recognition
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies.
Public Law, CFR Citation(s) and Procode(s)*
Regulation Number Device Name Device Class Product Code
§866.1640 Manual Antimicrobial Susceptibility Test Systems Class 2 JWY
SHORT-TERM ANTIMICROBIAL SUSCEPTIBILITY TEST (AST) SYSTEM
§866.1645 System, Test, Automated, Antimicrobial Susceptibility, Short Incubation Class 2 LON
Relevant FDA Guidance and/or Supportive Publications*
Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems, Issued March 2007.
FDA Technical Contact
 Ribhi Shawar
  FDA/OC/CDRH/OPEQ/OIDRH/DCTD/DB/
  301-796-6698
  ribhi.shawar@fda.hhs.gov
Standards Development Organization
CLSI Clinical Laboratory Standards Institute https://clsi.org/
FDA Specialty Task Group (STG)
InVitro Diagnostics
*These are provided as examples and others may be applicable.
-
-